Published in Am J Pathol on September 01, 2006
Omega-3 vs Very Low Calorie Diet for Liver Size Reduction | NCT03132662
The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol (2010) 2.50
Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol (2012) 2.08
Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling. PPAR Res (2007) 1.88
Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol (2011) 1.85
Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology (2009) 1.78
Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. Hepatology (2008) 1.76
Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut (2010) 1.59
High fat diet subverts hepatocellular iron uptake determining dysmetabolic iron overload. PLoS One (2015) 1.44
Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats. Dig Dis Sci (2009) 1.43
Oxidative stress, nitric oxide, and diabetes. Rev Diabet Stud (2010) 1.43
(n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights. Adv Nutr (2011) 1.39
The Role of PPARs in Lung Fibrosis. PPAR Res (2007) 1.37
Metabolic syndrome, aging and involvement of oxidative stress. Aging Dis (2015) 1.22
Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol (2012) 1.21
Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol (2008) 1.17
Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol (2012) 1.17
Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol (2008) 1.14
Oxidative stress in diabetes: implications for vascular and other complications. Int J Mol Sci (2013) 1.13
Peroxisome proliferator activated receptors and lipoprotein metabolism. PPAR Res (2008) 1.12
Activation of peroxisome proliferator-activated receptor-alpha stimulates both differentiation and fatty acid oxidation in adipocytes. J Lipid Res (2011) 1.11
Garlic-derived S-allylmercaptocysteine is a hepato-protective agent in non-alcoholic fatty liver disease in vivo animal model. Eur J Nutr (2012) 1.11
Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. Am J Transl Res (2010) 1.10
Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance. Diabetes (2013) 1.08
Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol (2010) 1.07
The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Lipids Health Dis (2010) 1.03
New insights from rodent models of fatty liver disease. Antioxid Redox Signal (2011) 1.03
Changes in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob mice. PLoS One (2010) 1.01
High fat diet-induced non alcoholic fatty liver disease in rats is associated with hyperhomocysteinemia caused by down regulation of the transsulphuration pathway. Lipids Health Dis (2011) 0.98
Limited therapeutic effect of N-acetylcysteine on hepatic insulin resistance in an experimental model of alcohol-induced steatohepatitis. Alcohol Clin Exp Res (2011) 0.98
Epigenetic effects of human breast milk. Nutrients (2014) 0.96
Mitochondria and redox signaling in steatohepatitis. Antioxid Redox Signal (2011) 0.96
High Fat Diet Induces Liver Steatosis and Early Dysregulation of Iron Metabolism in Rats. PLoS One (2013) 0.96
Experimental models of non-alcoholic fatty liver disease in rats. World J Gastroenterol (2014) 0.96
Effects of sodium butyrate and its synthetic amide derivative on liver inflammation and glucose tolerance in an animal model of steatosis induced by high fat diet. PLoS One (2013) 0.92
Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame. Dig Dis Sci (2015) 0.91
Hepatic steatosis in n-3 fatty acid depleted mice: focus on metabolic alterations related to tissue fatty acid composition. BMC Physiol (2008) 0.91
Obstructive sleep apnea syndrome and fatty liver: association or causal link? World J Gastroenterol (2010) 0.90
Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol (2015) 0.88
High fat diet induced hepatic steatosis and insulin resistance: Role of dysregulated ceramide metabolism. Hepatol Res (2011) 0.88
Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats. PLoS One (2014) 0.87
CEACAM1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH). Semin Immunopathol (2013) 0.87
Effect of a dietary intervention and n-3 fatty acid supplementation on measures of serum lipid and insulin sensitivity in persons with HIV. Am J Clin Nutr (2009) 0.87
Inhibiting monoacylglycerol acyltransferase 1 ameliorates hepatic metabolic abnormalities but not inflammation and injury in mice. J Biol Chem (2014) 0.86
Exercise and Omega-3 Polyunsaturated Fatty Acid Supplementation for the Treatment of Hepatic Steatosis in Hyperphagic OLETF Rats. J Nutr Metab (2011) 0.86
Impact of new-generation lipid emulsions on cellular mechanisms of parenteral nutrition-associated liver disease. Adv Nutr (2014) 0.85
n-3 fatty acids ameliorate hepatic steatosis and dysfunction after LXR agonist ingestion in mice. Biochim Biophys Acta (2011) 0.84
Insulin resistance in insulin-resistant and diabetic hamsters (Mesocricetus auratus) is associated with abnormal hepatic expression of genes involved in lipid and glucose metabolism. Comp Med (2009) 0.84
Coexistence of hyperlipidemia and acute cerebral ischemia/reperfusion induces severe liver damage in a rat model. World J Gastroenterol (2012) 0.81
Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice. PLoS One (2015) 0.80
Reduced dietary omega-6 to omega-3 fatty acid ratio and 12/15-lipoxygenase deficiency are protective against chronic high fat diet-induced steatohepatitis. PLoS One (2014) 0.80
Pleiotropic effects of rosuvastatin on the glucose metabolism and the subcutaneous and visceral adipose tissue behavior in C57Bl/6 mice. Diabetol Metab Syndr (2013) 0.80
Simultaneous changes in high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis and those underlying molecular mechanisms in novel SHRSP5/Dmcr rat. Environ Health Prev Med (2012) 0.79
Ameliorative potential of Tamarindus indica on high fat diet induced nonalcoholic fatty liver disease in rats. ScientificWorldJournal (2014) 0.78
Coenzyme Q metabolism is disturbed in high fat diet-induced non-alcoholic fatty liver disease in rats. Int J Mol Sci (2012) 0.76
Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease. J Clin Res Pediatr Endocrinol (2015) 0.76
Enteral High Fat-Polyunsaturated Fatty Acid Blend Alters the Pathogen Composition of the Intestinal Microbiome in Premature Infants with an Enterostomy. J Pediatr (2016) 0.76
Alcoholic vs non-alcoholic fatty liver in rats: distinct differences in endocytosis and vesicle trafficking despite similar pathology. BMC Gastroenterol (2016) 0.76
Regulation of Cholesterol Metabolism in Liver: Link to NAFLD and Impact of n-3 PUFAs. J Lifestyle Med (2013) 0.75
Ameliorative effects of Compound K and ginsenoside Rh1 on non-alcoholic fatty liver disease in rats. Sci Rep (2017) 0.75
Extract of a polyherbal formulation ameliorates experimental nonalcoholic steatohepatitis. J Tradit Complement Med (2015) 0.75
A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem (1957) 173.99
Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem (1979) 41.65
A central role for JNK in obesity and insulin resistance. Nature (2002) 17.27
Insulin signalling and the regulation of glucose and lipid metabolism. Nature (2001) 16.41
Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 13.21
IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med (2005) 12.07
Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med (2005) 10.88
Thiazolidinediones. N Engl J Med (2004) 9.42
Molecular mediators of hepatic steatosis and liver injury. J Clin Invest (2004) 9.40
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology (2003) 9.36
Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med (2002) 8.95
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem (2004) 7.91
Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med (2005) 6.04
The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest (2003) 5.32
Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med (2000) 4.92
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism (1995) 4.02
Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology (2005) 3.44
Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest (2001) 3.41
Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology (2005) 3.35
Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (2004) 3.23
Model of nonalcoholic steatohepatitis. Am J Clin Nutr (2004) 3.13
Retinoid x receptor heterodimers in the metabolic syndrome. N Engl J Med (2005) 3.12
Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res (2000) 3.02
Nonalcoholic steatohepatitis. Semin Liver Dis (2004) 2.89
Animal models of steatosis. Semin Liver Dis (2001) 2.88
JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem (2005) 2.76
Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology (2005) 2.72
JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology (2006) 2.70
Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol Endocrinol (2004) 2.68
Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J Clin Invest (1989) 2.46
Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) (2004) 2.45
Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology (2003) 2.44
Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology (2003) 2.40
From fat to inflammation. Gastroenterology (2006) 2.35
Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes (1999) 2.25
Resistance of rat hepatocytes against bile acid-induced apoptosis in cholestatic liver injury is due to nuclear factor-kappa B activation. J Hepatol (2003) 2.24
Fat, carbohydrate, and calories in the development of diabetes and obesity in the C57BL/6J mouse. Metabolism (2004) 2.04
Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology (2004) 1.98
Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. J Biol Chem (1996) 1.88
Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem (2005) 1.80
Differential requirement for c-Jun NH2-terminal kinase in TNFalpha- and Fas-mediated apoptosis in hepatocytes. FASEB J (2004) 1.76
Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes (2003) 1.71
Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2004) 1.70
Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther (2006) 1.58
Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia (2006) 1.57
Inhibition of the NA(+)/H(+) exchanger reduces rat hepatic stellate cell activity and liver fibrosis: an in vitro and in vivo study. Gastroenterology (2001) 1.57
Fibrogenic effect of oxidative stress on rat hepatic stellate cells. Hepatology (1998) 1.55
Quantification of lipid peroxidation in tissue extracts based on Fe(III)xylenol orange complex formation. Free Radic Biol Med (1995) 1.51
The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol (2005) 1.49
Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology (2005) 1.34
Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2005) 1.27
Adiponectin, a fat cell product, influences the earliest lymphocyte precursors in bone marrow cultures by activation of the cyclooxygenase-prostaglandin pathway in stromal cells. J Immunol (2003) 1.10
Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription. Am J Physiol Gastrointest Liver Physiol (2001) 1.08
Expression of the peroxisome proliferator-activated receptor gene is decreased in experimental alcoholic liver disease. Life Sci (1995) 1.06
PPARalpha in the pathogenesis of fatty liver disease. Hepatology (2004) 1.05
Regulation of ERK/JNK/p70S6K in two rat models of liver injury and fibrosis. J Hepatol (2003) 0.99
TNF-alpha downregulates the peroxisome proliferator activated receptor-alpha and the mRNAs encoding peroxisomal proteins in rat liver. FEBS Lett (1997) 0.95
TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med (2007) 9.77
Adherence to Mediterranean diet and health status: meta-analysis. BMJ (2008) 4.16
Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr (2010) 3.99
CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest (2009) 3.62
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest (2008) 2.89
Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology (2010) 2.37
Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology (2002) 2.26
Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology (2009) 2.25
Fate-mapping evidence that hepatic stellate cells are epithelial progenitors in adult mouse livers. Stem Cells (2008) 2.24
From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis (2010) 2.24
Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am J Physiol Gastrointest Liver Physiol (2009) 2.23
Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells. J Hepatol (2007) 2.16
Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int (2011) 2.14
Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology (2006) 1.98
Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology (2006) 1.86
Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology (2014) 1.86
Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells. Gastroenterology (2008) 1.84
Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology (2009) 1.83
Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology (2010) 1.82
Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology (2008) 1.79
Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology (2009) 1.79
Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology (2009) 1.73
Accumulation of hedgehog-responsive progenitors parallels alcoholic liver disease severity in mice and humans. Gastroenterology (2008) 1.71
Signals from dying hepatocytes trigger growth of liver progenitors. Gut (2010) 1.67
Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut (2010) 1.59
c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology (2009) 1.59
Hedgehog signaling is critical for normal liver regeneration after partial hepatectomy in mice. Hepatology (2010) 1.57
Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol (2006) 1.57
Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP3/CaMK I/CREB pathway. Am J Physiol Cell Physiol (2008) 1.57
cAMP stimulates the secretory and proliferative capacity of the rat intrahepatic biliary epithelium through changes in the PKA/Src/MEK/ERK1/2 pathway. J Hepatol (2004) 1.46
Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology (2005) 1.42
Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology (2013) 1.40
Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. Hepatology (2008) 1.40
Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin. Gastroenterology (2005) 1.38
Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J Biol Chem (2010) 1.33
Insomnia and risk of cardiovascular disease: a meta-analysis. Eur J Prev Cardiol (2012) 1.30
Nerve growth factor modulates the proliferative capacity of the intrahepatic biliary epithelium in experimental cholestasis. Gastroenterology (2004) 1.24
Hepatic accumulation of Hedgehog-reactive progenitors increases with severity of fatty liver damage in mice. Lab Invest (2007) 1.24
H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway. Lab Invest (2007) 1.24
Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. Lab Invest (2010) 1.23
gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res (2005) 1.23
Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int (2013) 1.22
Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha. Hepatology (2002) 1.20
Coffee consumption and risk of coronary heart disease: a meta-analysis. Nutr Metab Cardiovasc Dis (2006) 1.20
Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Ann Rheum Dis (2012) 1.19
Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res (2008) 1.18
The role of Hedgehog signaling in fibrogenic liver repair. Int J Biochem Cell Biol (2010) 1.18
Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/-) mice with catecholaminergic polymorphic ventricular tachycardia. J Mol Cell Cardiol (2010) 1.15
Alpha-1 antitrypsin Z protein (PiZ) increases hepatic fibrosis in a murine model of cholestasis. Hepatology (2007) 1.15
Congenital fibrinogen disorders: an update. Semin Thromb Hemost (2013) 1.13
The gluten-free diet: safety and nutritional quality. Nutrients (2010) 1.13
Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor. Gastroenterology (2005) 1.12
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer (2014) 1.11
Activation of Rac1 promotes hedgehog-mediated acquisition of the myofibroblastic phenotype in rat and human hepatic stellate cells. Hepatology (2010) 1.11
Role of NADPH oxidases in liver fibrosis. Antioxid Redox Signal (2014) 1.10
Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition. Liver Int (2008) 1.09
Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med (2006) 1.09
Administration of r-VEGF-A prevents hepatic artery ligation-induced bile duct damage in bile duct ligated rats. Am J Physiol Gastrointest Liver Physiol (2006) 1.08
Role and cellular source of nicotinamide adenine dinucleotide phosphate oxidase in hepatic fibrosis. Hepatology (2010) 1.08
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer (2014) 1.08
Role for hedgehog pathway in regulating growth and function of invariant NKT cells. Eur J Immunol (2009) 1.07
Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. J Exp Clin Cancer Res (2010) 1.07
Heterogeneity of the intrahepatic biliary epithelium. World J Gastroenterol (2006) 1.07
Alpha-1 adrenergic receptor agonists modulate ductal secretion of BDL rats via Ca(2+)- and PKC-dependent stimulation of cAMP. Hepatology (2004) 1.06
Taurocholate prevents the loss of intrahepatic bile ducts due to vagotomy in bile duct-ligated rats. Am J Physiol Gastrointest Liver Physiol (2003) 1.05
Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J (2004) 1.05
Cholangiocyte injury and ductopenic syndromes. Semin Liver Dis (2007) 1.05
Dopaminergic inhibition of secretin-stimulated choleresis by increased PKC-gamma expression and decrease of PKA activity. Am J Physiol Gastrointest Liver Physiol (2002) 1.04
Early response of alpha2(I) collagen to acetaldehyde in human hepatic stellate cells is TGF-beta independent. Hepatology (2005) 1.04
Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts. Am J Pathol (2006) 1.03
Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology (2007) 1.03
Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. Int J Food Sci Nutr (2010) 1.03
Adrenergic receptor agonists prevent bile duct injury induced by adrenergic denervation by increased cAMP levels and activation of Akt. Am J Physiol Gastrointest Liver Physiol (2005) 1.02